Eric Jonasch, MD, discusses the next research steps with the HIF-2α inhibitor belzutifan in patients with renal cell carcinoma. At the 2022 ASCO Annual Meeting, Jonasch shared findings from the abstract, “Phase 1 LITESPARK-001 (MK-6482-001) study of the HIF-2α inhibitor belzutifan in advanced solid tumors: Update of the clear cell renal cell carcinoma (ccRCC) cohort with more than 3 years of total follow-up.”
In the video, Jonasch says based on the efficacy in LITESPARK-001, the phase 3 LITESPARK-005 study has already been launched. Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.